LYEL Lyell Immunopharma, Inc.
Financings ·
Lyell Immunopharma agreed to pay $40 million in cash and issue 1.9 million shares for exclusive rights to LYL273, a CAR T candidate for colorectal cancer that has been tested in 12 patients. The deal also carries more shares, large milestone payments and tiered royalties, and the company says its cash lasts into 2027 once it closes.
Lyell's private placement starts with about $50 million at $13.32 per share. A second $50 million at $25.61 per share depends on a milestone within 12 months.
Lyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning.
Lyell adds IMPT-314, a CAR T-cell candidate, through the ImmPACT Bio deal. The release gives no purchase price and no cash balance, and says cash will fund operations into 2027.
Lyell Immunopharma is a late-stage clinical cell therapy company advancing next-generation autologous CAR T-cell product candidates for patients with cancer. Its lead product candidate, rondecabtagene autoleucel, also called ronde-cel or LYL314, is a dual-targeting CD19/CD20 CAR T-cell therapy designed to increase complete response rates and prolong duration of response compared with approved first-generation CD19 CAR T-cell products in relapsed or refractory large B-cell lymphoma. Ronde-cel is in the pivotal single-arm PiNACLE trial in the third-line and later setting and in the randomized Phase 3 PiNACLE-H2H trial, which compares it with investigator's choice of axicabtagene ciloleucel or lisocabtagene maraleucel in the second-line setting. Patient dosing in PiNACLE-H2H commenced in February 2026. In November 2025 Lyell acquired an exclusive global license, excluding mainland China, Hong Kong, Macau and Taiwan, for LYL273, a guanylyl cyclase C-targeted CAR T-cell candidate previously known as GCC19CART, from Innovative Cellular Therapeutics. LYL273 is in an ongoing Phase 1 trial in advanced metastatic colorectal cancer. The company is also developing next-generation solid tumor candidates that use anti-exhaustion and arming technologies.
| Product or program | What it is | Stage |
|---|---|---|
| Rondecabtagene autoleucel (ronde-cel, LYL314) | Dual-targeting CD19/CD20 autologous CAR T-cell therapy for large B-cell lymphoma | Pivotal PiNACLE trial; Phase 3 PiNACLE-H2H dosing |
| LYL273 | Autologous guanylyl cyclase C-targeted CAR T-cell therapy for colorectal cancer | Phase 1 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $36,000 | $61,000 |
| Net income (loss) | -$274.4 million | -$343.0 million |
| Cash from operations | -$150.0 million | -$162.4 million |
| Cash and equivalents | $60.2 million | $105.6 million |
| Short-term investments | $187.0 million | $264.9 million |
Our latest story on this, dated Jul 25, 2025: "Lyell Immunopharma signs private placement of up to $100 million at $13.32 per share". The story links the filing or release it is based on. Read the story.
Lyell Immunopharma, Inc. trades under the ticker LYEL on NASDAQ.
Lyell Immunopharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lyell Immunopharma, Inc. is 1806952. Its filings are on SEC EDGAR.
24,505,141 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Lyell Immunopharma, Inc. under United States.
Our directory classifies Lyell Immunopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lyell Immunopharma, Inc. is US55083R2031.
aibio.space lists Lyell Immunopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lyell Immunopharma is a late-stage clinical cell therapy company advancing next-generation autologous CAR T-cell product candidates for patients with cancer. Its lead product candidate, rondecabtagene autoleucel, also called ronde-cel or LYL314, is a dual-targeting CD19/CD20 CAR T-cell therapy designed to increase complete response rates and prolong duration of response compared with approved first-generation CD19 CAR T-cell products in relapsed or refractory large B-cell lymphoma.
Rondecabtagene autoleucel (ronde-cel, LYL314): Dual-targeting CD19/CD20 autologous CAR T-cell therapy for large B-cell lymphoma Stage: Pivotal PiNACLE trial; Phase 3 PiNACLE-H2H dosing.
LYL273: Autologous guanylyl cyclase C-targeted CAR T-cell therapy for colorectal cancer Stage: Phase 1.
$36,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Lyell Immunopharma, Inc. reported a net loss of $274.4 million for the fiscal year ended Dec 31, 2025, and used $150.0 million of cash in operations, per its annual report to the SEC.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio